Afatinib—new therapy option for EGFR-mutant lung cancer

被引：0

作者：

Helena A. Yu

William Pao

机构：

[1] Thoracic Oncology Service,Division of Solid Tumor Oncology, Department of Medicine

[2] Memorial Sloan–Kettering Cancer Center,Division of Hematology/Oncology

[3] Weill Cornell Medical College,undefined

[4] Vanderbilt Ingram Cancer Center,undefined

来源：

Nature Reviews Clinical Oncology | 2013年 / 10卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Afatinib improves progression-free survival compared with cisplatin and pemetrexed as first- line treatment for patients with EGFR mutant lung cancersAfatinib monotherapy has limited efficacy in patients with EGFR-mutant lung cancers with disease progression on erlotinib or gefitinibErlotinib, gefitinib and afatinib are all viable treatment options for the first-line treatment of patients with EGFR-mutant non-small-cell lung cancers

引用

页码：551 / 552

页数：1

共 8 条

[1]

Pao W(2010)Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat. Rev. Cancer 10 760-774

[2]

Chmielecki J(2005)Erlotinib in previously treated non-small-cell lung cancer N. Engl. J. Med. 353 123-132

[3]

Shepherd FA(2011)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol. 12 735-742

[4]

Zhou C(2012)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol. 13 239-246

[5]

Rosell R(2013)Analysis of mechanisms of acquired resistance to EGFR TKI therapy in 155 patients with Clin. Cancer Res. 19 2240-2247

[6]

Yu H(2012)-mutant lung cancers Lancet Oncol. 13 528-538

[7]

Miller VA(2012)Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Ann. Oncol. 23 a12270-undefined

[8]

Janjigian YY(undefined)Activity of afatinib/cetuximab in patients (pts) with undefined undefined undefined-undefined

← 1 →